The blind spot of Mendelian diseases: hypomyelination and the barrier of noncoding regions This neurodevelopmental syndrome, characterized by distinctive white‑matter hypomyelination, microcephaly, and severe intellectual disability on magnetic resonance imaging (MRI), could not be explained by conventional protein‑coding (exome‑focused) sequencing. The pathogenic cause resided in a noncoding RNA (ncRNA) region that does not encode protein. In particular, short nuclear small RNAs (snRNAs) remain difficult to annotate and functionally validate even with whole‑genome sequencing (WGS), leaving many rare genetic disorders in a persistent black box.

Biallelic variants in RNU4-2 and the mechanism of splicing runaway Through high‑resolution WGS cohort analysis centered on patient pedigrees, the team consistently identified recessive‑pattern biallelic variants in RNU4-2, the gene encoding the U4 snRNA, a core component of the major spliceosome. Functional studies demonstrated that nucleotide alterations in this tiny RNA strand trigger widespread mis‑splicing during post‑transcriptional processing. Consequently, the maturation of target genes essential for glial development and myelination is fundamentally blocked, leading to severe white‑matter pathology.

Academic significance of the Author Correction: the importance of precise annotation The distinctive aspect of this dataset is the inclusion of an Author Correction published in Nature Genetics. The authors voluntarily acknowledged and corrected a positional annotation error for the reported RNU4‑2 nucleotide variant (e.g., c.10A>G) observed in a specific patient cohort. Noncoding regions rich in repetitive sequences such as snRNA paralogs are highly prone to false‑positive calls or positional mismatches during next‑generation sequencing (NGS) mapping. This correction supplies a definitive reference that will prevent false negatives when designing commercial clinical diagnostic panels.

Increased WGS diagnostic yield and securing RNA‑correction therapeutic targets The discovery and its subsequent correction are critical because they provide an immediate solution for the WGS diagnostic pipelines of countless undiagnosed rare neuro‑developmental patients worldwide. By moving beyond the protein‑coding focus of conventional exome sequencing (WES) and incorporating snRNA regions into diagnostic panels, the diagnostic yield can be dramatically improved. Moreover, mapping the RNU4‑2‑driven splicing error signature establishes a concrete target for ultra‑precise RNA‑correction therapies—such as AAV‑mediated gene replacement or antisense oligonucleotides (ASOs)—that aim to reverse hypomyelination at its root.